Back to Search
Start Over
The effects of serine proteinase inhibitors on bone resorption in vitro.
- Source :
-
The Journal of endocrinology [J Endocrinol] 2003 Sep; Vol. 178 (3), pp. 437-47. - Publication Year :
- 2003
-
Abstract
- The aims of this study were to identify the role and sites of action of serine proteinases (SPs) in bone resorption, a process which involves a cascade of events, the central step of which is the removal of bone matrix by osteoclasts (OCs). This resorbing activity, however, is also determined by recruitment of new OCs to future resorption sites and removal of the osteoid layer by osteoblasts (OBs), which enables OCs to gain access to the underlying mineralized bone. The resorption systems we have studied consisted of (i) neonatal calvarial explants, (ii) isolated OCs cultured on ivory slices, (iii) mouse OBs cultured on either radiolabelled type I collagen films or bone-like matrix, (iv) bone marrow cultures to assess OC formation and (v) 17-day-old fetal mouse metatarsal bone rudiments to assess OC migration and fusion. Two separate SP inhibitors, aprotinin and alpha(2)-antiplasmin dose-dependently inhibited (45)Ca release from neonatal calvarial explants: aprotinin (10(-6) M) was the most effective SP inhibitor, producing a maximum inhibitory effect of 55.9%. Neither of the SP inhibitors influenced either OC formation or OC resorptive activity. In contrast, each SP inhibitor dose-dependently inhibited OB-mediated degradation of both type I collagen fibrils and non-mineralized bone matrix. In 17-day-old metatarsal explants aprotinin produced a 55% reduction in the migration of OCs from the periosteum to the mineralized matrix after 3 days in culture but after 6 days in culture aprotinin was without effect on OC migration. Primary mouse osteoblasts expressed mRNA for urokinase type plasminogen activator (uPA), tIssue type plasminogen activator (tPA), the type I receptor for uPA, plasminogen activator inhibitor types I and II and the broad spectrum serine proteinase inhibitor, protease nexin I. In situ hybridization demonstrated expression of tPA and uPA in osteoclasts disaggregated from 6-day-old mouse long bones. We propose that the regulation of these various enzyme systems within bone tIssue determines the sites where bone resorption will be initiated.
- Subjects :
- Amyloid beta-Protein Precursor
Animals
Animals, Newborn
Aprotinin pharmacology
Bone Marrow Cells
Bone and Bones drug effects
Carrier Proteins genetics
Cells, Cultured
Culture Techniques
Dose-Response Relationship, Drug
Gene Expression
Mice
Osteoblasts drug effects
Osteoblasts metabolism
Osteoclasts drug effects
Osteoclasts metabolism
Plasminogen Activator Inhibitor 1 genetics
Plasminogen Activator Inhibitor 2 genetics
Protease Nexins
Receptors, Cell Surface genetics
Receptors, Urokinase Plasminogen Activator
Reverse Transcriptase Polymerase Chain Reaction
Tissue Plasminogen Activator genetics
Urokinase-Type Plasminogen Activator genetics
alpha-2-Antiplasmin pharmacology
Bone Resorption metabolism
Bone and Bones physiology
Serine Proteinase Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 0022-0795
- Volume :
- 178
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The Journal of endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 12967336
- Full Text :
- https://doi.org/10.1677/joe.0.1780437